Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Deferred Taxes: 2023-2025

Historic Deferred Taxes for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to -$2.4 million.

  • Iovance Biotherapeutics' Deferred Taxes fell 58.12% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$696,000, marking a year-over-year increase of 88.68%. This contributed to the annual value of -$2.8 million for FY2024, which is 18.71% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Deferred Taxes stood at -$2.4 million, which was down 220.98% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Deferred Taxes ranged from a high of $2.0 million in Q2 2025 and a low of -$2.4 million during Q3 2025.
  • For the 3-year period, Iovance Biotherapeutics' Deferred Taxes averaged around -$856,200, with its median value being -$1.4 million (2024).
  • Per our database at Business Quant, Iovance Biotherapeutics' Deferred Taxes tumbled by 205.66% in 2024 and then spiked by 236.35% in 2025.
  • Iovance Biotherapeutics' Deferred Taxes (Quarterly) stood at -$1.8 million in 2023, then soared by 188.63% to $1.6 million in 2024, then slumped by 58.12% to -$2.4 million in 2025.
  • Its last three reported values are -$2.4 million in Q3 2025, $2.0 million for Q2 2025, and -$1.8 million during Q1 2025.